Skip to main content

Table 2 Clinical characteristics of patients according to PLR

From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

Variable PLR ≤148 (N = 74) PLR > 148 (N = 63) P value
Age, yr 64 (58, 73) 64 (54, 69) 0.247
Sex    1.000
 Male 45 (60.8%) 38 (60.3%)  
 Female 29 (39.2%) 25 (39.7%)  
BMI 23.7 (22.2, 25.7) 23.0 (22.0, 24.5) 0.119
ECOG Performance status    1.000
 0 35 (47.3%) 29 (46.0%)  
  ≥ 1 39 (52.7%) 34 (54.0%)  
Liver cirrhosis 10 (13.5%) 5 (7.9%) 0.443
Diabetes mellitus 15 (20.3%) 10 (15.9%) 0.658
Charlson Commorbidity Index    0.595
 0 45 (60.8%) 42 (66.7%)  
  ≥ 1 29 (39.2%) 21 (33.3%)  
Biliary drainage 6 (8.1%) 9 (14.3%) 0.379
Tumor size, cm 7.2 (5.4, 10.0) 7.0 (4.5, 9.6) 0.246
Major vascular invasion 53 (71.6%) 36 (57.1%) 0.112
Hilar invasion 9 (12.2%) 7 (11.1%) 1.000
Liver metastasis 27 (36.5%) 28 (44.4%) 0.440
Extrahepatic organ metastasis 38 (51.4%) 37 (58.7%) 0.489
Distant lymph node metastasis 47 (63.5%) 43 (68.3%) 0.688
Number of metastatic sites    0.090
 0 10 (13.5%) 2 (3.2%)  
 1 27 (36.5%) 23 (36.5%)  
  ≥ 2 37 (50.0%) 38 (60.3%)  
Baseline laboratory findings
 Neutrophil count, cells/μL 5288 (3768, 6403) 5792 (4663, 7231) 0.063
 Lymphocyte count, cells/μL 1935 (1547, 2271) 1377 (1119, 1623) < 0.001
 Monocyte count, cells/μL 637 (509, 808) 629 (506, 756) 0.837
 Platelet count, 103 cells/μL 199 (163, 255) 261 (224, 303) < 0.001
 Total bilirubin, mg/dL 0.7 (0.6, 0.9) 0.7 (0.5, 0.9) 0.979
 ALP, IU/L 129 (93, 225) 164 (115, 259) 0.074
 Albumin, g/dL 4.0 (3.7, 4.2) 3.8 (3.5, 4.1) 0.030
 CA 19–9, U/mL 652.5 (44.6, 4830.0) 183.4 (16.1, 2955.0) 0.211
  1. Abbreviations: PLR Platelet-to-lymphocyte ratio; BMI Body mass index; ECOG Eastern Cooperative Oncology Group; ALP Alkaline phosphatase; CA 19–9 Carbohydrate antigen 19–9
  2. Data are presented as no. (%) or median (interquartile range)